GlassScriptPhysician profile
Ryan K Judson
NPI 1285936930
$10,033.78
in general payments reported to CMS, 2019-2025
25 companies · $862 in 2025
The $862 reported for 2025 was more than what 82% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $5,023 · 2022: $1,559 · 2023: $1,445 · 2024: $1,146 · 2025: $862.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,453.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,452.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,845.46 | 2021-2025 | Linq II, Micra, Selectsecure |
| Novartis Pharmaceuticals Corporation | $1,702.41 | 2021-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,357.14 | 2021-2025 | Lifevest |
| Boston Scientific Corporation | $584.32 | 2021-2025 | Watchman Flx, Watchman Access System, Eluvia |
| Astrazeneca Pharmaceuticals LP | $576.07 | 2021-2024 | Farxiga, Brilinta |
| Abbott Laboratories | $368.05 | 2021-2025 | Accent, Aveir, Gallant |
| Abiomed | $254.09 | 2021-2024 | |
| Atricure, INC. | $229.88 | 2022-2024 | |
| Daiichi Sankyo INC. | $193.44 | 2021-2025 | Injectafer |
| Janssen Pharmaceuticals, INC | $148.21 | 2021-2023 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $137.82 | 2023-2025 | Uptravi, Opsumit |
| Merck Sharp & Dohme LLC | $99.66 | 2022-2025 | Verquvo |
| Penumbra, INC. | $97.41 | 2022 | |
| Pfizer INC. | $65.04 | 2021-2023 | |
| Cardiovascular Systems INC. | $63.93 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $63.13 | 2024-2025 | |
| Amgen INC. | $49.30 | 2023-2025 | Repatha, Repatha |
| Kiniksa Pharmaceuticals, LTD. | $41.93 | 2023 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.37 | 2021-2024 | Jardiance |
| Kiniksa Pharmaceuticals International, Plc | $29.56 | 2024 | Arcalyst |
| Amarin Pharma, INC. | $21.02 | 2021 | |
| Astellas Pharma US INC | $18.69 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $16.80 | 2023 | Inpefa |
| Irhythm Technologies, INC. | $16.73 | 2022 | |
| Sanara Medtech INC. | $14.32 | 2025 | Biasurge |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Judson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.